1. Scrip
  2. >>R&D

Biopharma Leaders Talk Radical Steps, Regulatory Reform, Open AI To Spur India R&D

 
• By Anju Ghangurde

Biopharma experts including Nobel Laureate Professor Jack Szostak share their views on emerging innovation ecosystems and how India can get it right as it seeks to shift gears in R&D. Panelists noted that VC investments can be a mixed bag, called for regulatory vision that ensures safety alongside accelerated pathways like the LPAD in the US and also ‘open” AI platforms.

L-R: Dr. Ajit Rangnekar, Dr. Harish Iyer, Dr. Yamuna Krishnan, Dr. Radha Rangarajan, Mr Satish Reddy, Professor Jack W. Szostak, Dr. Guru N. Reddy, Dr. Shridhar Narayanan, Dr. Ravindranathan, Dr. Murali Ramachandra, Dr. Srinivas Oruganti, Anju Ghangurde, Tejasvi Poorna Chandra and Dinesh Reddy Musukula. • Source: Dr Reddy's Laboratories

A high-profile biopharma panel that included Nobel Laureate Professor Jack W. Szostak recently discussed how India could invigorate its innovation ecosystem and support cutting-edge R&D. The prescription was clear: think radical, think artificial intelligence, channelize large investments, re-imagine regulatory processes and take a leaf out of the China success story.

More from R&D

Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos

 
• By Joseph Haas

With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.

AbbVie On A STEAP Learning Curve In ADCs

 
• By Andrew McConaghie

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By Kevin Grogan

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Hengrui Renews Global Phase III Push As China Players Plan Pivotal Multinational Trials

 
• By Dexter Jie Yan

After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.

More from Scrip

AbbVie On A STEAP Learning Curve In ADCs

 
• By Andrew McConaghie

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By Kevin Grogan

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Hengrui Renews Global Phase III Push As China Players Plan Pivotal Multinational Trials

 
• By Dexter Jie Yan

After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.